Beta Bionics, Inc.
BBNX · NASDAQ Global Market · USD
16,52USD
−0,43 (−2,54 %)Stand 10. Nov., 21:00
Nachbörslich16,520,00 (0,00 %)19:30 ET
Vortag 16,95
Kennzahlen
- Eröffnung
- 16,56
- Vortag
- 16,95
- Tagesspanne
- 16,12 – 16,99
- 52 Wochen
- 8,80 – 32,71
- Volumen
- 658.982
- Ø Volumen
- 1,25 Mio.
- Börsenwert
- 743,23 Mio. $
- KGV
- -8,8
- Gewinn je Aktie (TTM)
- -1,87
- Dividendenrendite
- 0,0 %
- Beta
- 3,4
- Nächste Zahlen
- 16. Feb. 2027
Finanzen
| USD | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Umsatz | 100,25 Mio. | 65,12 Mio. | 12 Mio. | 179.000 |
| Herstellungskosten | 44,71 Mio. | 29,24 Mio. | 5,69 Mio. | 0 |
| Bruttogewinn | 55,54 Mio. | 35,89 Mio. | 6,31 Mio. | 179.000 |
| Forschung und Entwicklung | 34,79 Mio. | 26,18 Mio. | 17,94 Mio. | 31,43 Mio. |
| Vertrieb und Verwaltung | 92,43 Mio. | 54,96 Mio. | 24,22 Mio. | 33,5 Mio. |
| Operatives Ergebnis | −71,68 Mio. | −45,25 Mio. | −35,85 Mio. | −65,84 Mio. |
| EBITDA | −70,32 Mio. | −52,47 Mio. | −42,01 Mio. | −62,66 Mio. |
| Nettogewinn | −73,2 Mio. | −54,76 Mio. | −44,1 Mio. | −64,75 Mio. |
| Gewinn je Aktie (verwässert) | -1,81 | -1,28 | -1,03 | -1,51 |
Bewertung
Letzte 12 Monate
- KGV
- -8,8
- Kurs-Umsatz-Verhältnis
- 5,8
- Kurs-Buchwert-Verhältnis
- 1,9
- PEG
- 1,3
- Bruttomarge
- 58,6 %
- Operative Marge
- −72,7 %
- Nettomarge
- −65,3 %
- Verschuldungsgrad
- 0,0
- EV/EBITDA
- -8,0
- Eigenkapitalrendite
- −27,3 %
- Kapitalrendite (ROIC)
- −22,5 %
- Free-Cashflow-Rendite
- −8,9 %
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | |
|---|---|---|---|---|
| Bruttomarge | 55,4 % | 55,1 % | 52,6 % | 100,0 % |
| Operative Marge | −71,5 % | −69,5 % | −298,9 % | −36.784,4 % |
| Nettomarge | −73,0 % | −84,1 % | −367,6 % | −36.173,7 % |
| KGV | -16,8 | -18,5 | -22,9 | -15,6 |
| Kurs-Umsatz-Verhältnis | 12,3 | 15,6 | 84,4 | 5.657,9 |
| Kurs-Buchwert-Verhältnis | 4,3 | 13,3 | 17,3 | -6,0 |
| Verschuldungsgrad | 0,0 | 0,1 | 0,1 | -0,0 |
| Liquidität 3. Grades | 8,7 | 6,3 | 9,8 | 3,2 |
| Dividendenrendite | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
| Unternehmenswert | 1,21 Mrd. | 989,59 Mio. | 990,42 Mio. | 989,22 Mio. |
| EV/EBITDA | -17,2 | -18,9 | -23,6 | -15,8 |
| Eigenkapitalrendite | −25,5 % | −72,0 % | −75,2 % | 38,1 % |
| Kapitalrendite (ROIC) | −23,9 % | −34,8 % | −35,6 % | −238,3 % |
| Free-Cashflow-Rendite | −4,6 % | −5,1 % | −3,2 % | −6,0 % |
Wachstum
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | |
|---|---|---|---|---|
| Umsatz | +53,9 % | +442,9 % | +6.601,1 % | 0,0 % |
| Bruttogewinn | +54,8 % | +468,9 % | +3.424,0 % | 0,0 % |
| Operatives Ergebnis | −58,4 % | −26,2 % | +45,6 % | 0,0 % |
| Nettogewinn | −33,7 % | −24,2 % | +31,9 % | 0,0 % |
| Gewinn je Aktie | −41,4 % | −24,3 % | +31,8 % | 0,0 % |
| Freier Cashflow | −8,8 % | −57,3 % | +46,1 % | 0,0 % |
| Dividende je Aktie | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
Analysten
Einstufungen · Buy
- 0Stark kaufen
- 6Kaufen
- 3Halten
- 0Verkaufen
- 0Stark verkaufen
Kursziel
24,67
Durchschnitt · +49,33 %
Tief 16,00Aktuell 16,52Hoch 30,00
Schätzungen
| FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|
| Umsatz (Ø) | 125,54 Mio. | 184,65 Mio. | 284,54 Mio. |
| Umsatz (Tief – Hoch) | 125,13 Mio. – 125,84 Mio. | 176,24 Mio. – 189,06 Mio. | 265,51 Mio. – 338,73 Mio. |
| Gewinn je Aktie (Ø) | -2,04 | -2,13 | -1,59 |
| Gewinn je Aktie (Tief – Hoch) | -2,08 – -1,98 | -2,78 – -1,78 | -2,75 – -1,13 |
| Analysten | 7 | 7 | 10 |
Letzte Änderungen
- TD Cowen28. Okt. 2026Hold
- Piper Sandler28. Okt. 2026Overweight
- Truist Securities24. Sept. 2026Buy
- B of A Securities15. Sept. 2026Neutral
- Truist Securities15. Sept. 2026Buy
- Baird15. Sept. 2026Neutral
- Leerink Partners14. Sept. 2026Outperform
- Goldman Sachs15. Juli 2026Buy
Quartalszahlen
Nächste Zahlen: 16. Feb. 2027| Okt. 2026 | Juli 2026 | Apr. 2026 | Feb. 2026 | Okt. 2025 | Juli 2025 | Mai 2025 | März 2025 | |
|---|---|---|---|---|---|---|---|---|
| Gewinn je Aktie · Erwartet | -0,52 | -0,58 | -0,53 | -0,42 | -0,45 | -0,51 | -0,51 | -0,42 |
| Gewinn je Aktie · Tatsächlich | -0,52 | -0,53 | -0,49 | -0,30 | -0,33 | -0,39 | -0,52 | -1,82 |
| Abweichung | +0,64 % | +8,78 % | +7,55 % | +28,57 % | +26,67 % | +23,53 % | −1,96 % | −333,33 % |
| Umsatz · Tatsächlich | 35,51 Mio. | 32,01 Mio. | 27,63 Mio. | 32,12 Mio. | 27,25 Mio. | 23,24 Mio. | 17,64 Mio. | 20,44 Mio. |
Dividenden und Splits
Keine Dividenden gezahlt.
Aktiensplits
–
Eigentümer
Institutionen
Q2 2026 · 13F
- Anteil institutioneller Investoren
- 108,55 %
- Investoren mit 13F-Meldung
- 138
Größte Investoren
- EVENTIDE ASSET MANAGEMENT, LLC14,04 %6,25 Mio.
- SOLEUS CAPITAL MANAGEMENT, L.P.9,86 %4,39 Mio.
- MORGAN STANLEY9,58 %4,27 Mio.
- SANDS CAPITAL ALTERNATIVES, LLC8,32 %3,71 Mio.
- BLACKROCK, INC.7,50 %3,34 Mio.
- POINT72 ASSET MANAGEMENT, L.P.5,06 %2,25 Mio.
- VANGUARD CAPITAL MANAGEMENT LLC4,00 %1,78 Mio.
- VESTAL POINT CAPITAL, LP3,59 %1,6 Mio.
Insider-Geschäfte
- Feider Stephen5. Nov. 2026 · officer: Chief Financial OfficerKauf382 Aktien · 5,10
- Feider Stephen5. Nov. 2026 · officer: Chief Financial OfficerVerkauf382 Aktien · 17,04
- Feider Stephen5. Nov. 2026 · officer: Chief Financial OfficerVerkauf382 Aktien · 5,10
- Hopman Mark2. Nov. 2026 · officer: Chief Commercial OfficerVerkauf370 Aktien · 16,90
- Mensinger Mike27. Okt. 2026 · officer: Chief Product OfficerVerkauf2650 Aktien · 22,00
- Hopman Mark26. Okt. 2026 · officer: Chief Commercial OfficerVerkauf821 Aktien · 20,00
- Hopman Mark14. Okt. 2026 · officer: Chief Commercial OfficerVerkauf775 Aktien · 17,35
- Hopman Mark1. Okt. 2026 · officer: Chief Commercial OfficerVerkauf370 Aktien · 18,96
Vergleichbare Unternehmen
Über das Unternehmen
Beta Bionics, Inc. is a commercial-stage medical technology company dedicated to inventing, developing, and bringing to market solutions that improve the health and quality of life for individuals with diabetes who depend on insulin. The company's flagship product, the iLet Bionic Pancreas, is an automated insulin delivery system currently available for treating type 1 diabetes in adults and children aged six and older. In addition to its existing offering, Beta Bionics is actively developing several new innovations: a Patch Pump, designed as a tubeless insulin pump that adheres directly to the skin; the Bihormonal iLet, which integrates automated delivery of both insulin and glucagon; and an iLet system specifically adapted for individuals with insulin-dependent type 2 diabetes. To support its product pipeline, the company has forged strategic alliances, including a collaboration and licensing agreement with Xeris Pharmaceuticals, Inc. to develop and commercialize a glucagon formulation compatible with pumps. It also holds a development and commercialization agreement with Abbott Diabetes Care Inc. for an automated insulin delivery system. Established in 2015, Beta Bionics is headquartered in Irvine, California.
Führung
- Sean T. SaintPresident, Chief Executive Officer & Director
- Stephen H. FeiderChief Financial Officer, Treasurer & Secretary
- Mike MensingerChief Product Officer
- Mark HopmanChief Commercial Officer
- Blake BeberHead of Investor Relations
- Steven RussellChief Medical Officer
- CEO
- Sean T. Saint
- Mitarbeitende
- 422
- Hauptsitz
- Irvine, CA, US
- Sektor
- Healthcare
- Branche
- Medical - Devices
- Börsengang
- 30. Jan. 2025
- Website
- betabionics.com
Nachrichten
- Fool - Investing News · 9. Nov., 12:00Beta Bio: 3 Key Takeaways for Long-Term Investors
- GlobeNewsWire · 3. Nov., 17:32INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Beta Bionics, Inc. of Class Action Lawsuit and Upcoming Deadlines – BBNX
- PRNewsWire · 3. Nov., 17:20BBNX Deadline: BBNX Investors Have Opportunity to Lead Beta Bionics, Inc. Securities Fraud Lawsuit
- Business Wire · 3. Nov., 15:03BBNX Deadline Today: Rosen Law Firm Urges Beta Bionics, Inc. (NASDAQ: BBNX) Stockholders to Contact the Firm for Information About Their Rights
- GlobeNewsWire · 3. Nov., 10:11SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of November 3, 2026 in Beta Bionics, Inc. Lawsuit - BBNX
- Business Wire · 3. Nov., 9:56CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Beta Bionics (NASDAQ: BBNX) Investors of Securities Class Action Lawsuit Deadline on November 3, 2026
- GlobeNewsWire · 3. Nov., 9:00Beta Bionics, Inc. (NASDAQ:BBNX) SHAREHOLDER ALERT: Investors With Losses May Seek to Lead the Class Action in Beta Bionics, Inc. Securities Lawsuit - Contact Portnoy Law Firm
- GlobeNewsWire · 3. Nov., 7:30Beta Bionics Announces Participation at Upcoming Investor Conferences
- Newsfile Corp · 2. Nov., 22:01BBNX FINAL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important November 3 Deadline in Securities Class Action - BBNX
- GlobeNewsWire · 2. Nov., 21:04BBNX FINAL DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important November 3 Deadline in Securities Class Action - BBNX
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.